Wednesday, July 8, 2026
🇺🇸 FDA

pharma · COVID-19 · Hepatitis C · AVIR

Atea Pharmaceuticals

Atea Pharmaceuticals clinical programs — 37 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
225 Franklin St, Suite, 2100, Boston, Massachusetts 02110, US HQ
2014 Founded
57 Employees
Public company Type
AVIR · NYSE Ticker
Company details
Status
Public
HQ
225 Franklin St, Suite, 2100, Boston, Massachusetts 02110, US
Founded
2014
Employees
57
Programs
37
Drugs
29
Patents
35
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

Atea Pharmaceuticals projects

37 ClinicalTrials.gov programs sponsored by Atea Pharmaceuticals.

Atea Pharmaceuticals has 37 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

37 programs

Clinical programs

  1. AT-01B-008

    Atea Pharmaceuticals

    Chronic Hepatitis C Virus (HCV) Infection

    phase 3 small molecule active

    1 trial

  2. Bemnifosbuvir (BEM)

    Atea Pharmaceuticals

    Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection)

    phase 3 small molecule completed

    1 trial

  3. Bemnifosbuvir-Ruzasvir

    Atea Pharmaceuticals

    HEPATITIS C VIRUS CHRONIC INFECTION

    phase 3 small molecule active

    1 trial

  4. Bemnifosbuvir-Ruzasvir (BEM/RZR)

    Atea Pharmaceuticals

    HEPATITIS C VIRUS CHRONIC INFECTION

    phase 3 small molecule active

    1 trial

  5. RO7496998

    Atea Pharmaceuticals

    COVID-19

    phase 3 small molecule terminated

    1 trial

  6. AT-527

    Atea Pharmaceuticals

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  7. AT-527

    Atea Pharmaceuticals

    COVID-19

    phase 2 small molecule terminated

    2 trials

  8. AT-752

    Atea Pharmaceuticals

    Dengue Fever

    phase 2 small molecule terminated

    1 trial

  9. AT-777

    Atea Pharmaceuticals

    Hepatitis C

    phase 2 small molecule terminated

    1 trial

  10. Bemnifosbuvir

    Atea Pharmaceuticals

    Chronic Hepatitis C Virus

    phase 2 small molecule completed

    1 trial

  11. GHB11L1

    Atea Pharmaceuticals

    Influenza, Human

    phase 2 mab completed

    1 trial

  12. GHB16L2

    Atea Pharmaceuticals

    Influenza, Human

    phase 2 mab completed

    1 trial

  13. AT-01B-006

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  14. AT-527

    Atea Pharmaceuticals

    Chronic Hepatitis C

    phase 1 small molecule completed

    1 trial

  15. AT-527

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  16. AT-527

    Atea Pharmaceuticals

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  17. AT-527 (R07496998)

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  18. AT-527 + digoxin

    Atea Pharmaceuticals

    Healthy Volunteers Study

    phase 1 small molecule completed

    1 trial

  19. AT-527 550 mg + cyclosporine

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  20. AT-527 550 mg + midazolam

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  21. AT-527 Formulation 1

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  22. AT-527 fasted

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  23. AT-752

    Atea Pharmaceuticals

    Dengue

    phase 1 small molecule completed

    2 trials

  24. Bemnifosbuvir (BEM)

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule completed

    2 trials

  25. Bemnifosbuvir (BEM)

    Atea Pharmaceuticals

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  26. Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  27. Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule active

    1 trial

  28. Buprenorphine/Naloxone + BEM/RZR

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule active

    1 trial

  29. Cohort 1 BEM + Ruzasvir

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  30. Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  31. Drug: AT-527 + rosuvastatin

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  32. Ethinyl Estradioll/Levonorgestrel (EE/LNG)

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  33. GHB01L1

    Atea Pharmaceuticals

    Seasonal Human Influenza

    phase 1 mab completed

    1 trial

  34. GHB04L1

    Atea Pharmaceuticals

    Influenza, Avian

    phase 1 mab completed

    1 trial

  35. GHB04L1

    Atea Pharmaceuticals

    Influenza

    phase 1 mab completed

    1 trial

  36. Period 1: AT-527 550 mg

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  37. Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Atea Pharmaceuticals have?

37 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.